Both conventional and new anticancer drugs can frequently cause adverse cardiovascular effects, which can span from subclinical abnormalities to serious life-threatening and sometimes fatal events. This review examines the principal basic and clinical elements that may be of profit to identify, prevent and treat such toxicities. Clearly, the accomplishment of such objectives requires the strong commitment and cooperation of different professional figures including, but not limited to, pharmacologists, oncologists and cardiologists. The aspect of anticancer drug cardiotoxicity seems to be somehow underestimated, mainly due to inadequate reporting of adverse reactions from oncology drugs in the post-marketing setting. Thus, the implementation of pharmacovigilance is indispensable to rapidly and fully assess the safety of newer agents in real-life patients.

Bonura, F., Di Lisi, D., Novo, S., D'Alessandro, N. (2012). Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. CARDIOVASCULAR TOXICOLOGY, 12(2), 93-107 [10.1007/s12012-011-9141-z].

Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.

BONURA, Francesca;DI LISI, Daniela;NOVO, Salvatore;D'ALESSANDRO, Natale
2012-01-01

Abstract

Both conventional and new anticancer drugs can frequently cause adverse cardiovascular effects, which can span from subclinical abnormalities to serious life-threatening and sometimes fatal events. This review examines the principal basic and clinical elements that may be of profit to identify, prevent and treat such toxicities. Clearly, the accomplishment of such objectives requires the strong commitment and cooperation of different professional figures including, but not limited to, pharmacologists, oncologists and cardiologists. The aspect of anticancer drug cardiotoxicity seems to be somehow underestimated, mainly due to inadequate reporting of adverse reactions from oncology drugs in the post-marketing setting. Thus, the implementation of pharmacovigilance is indispensable to rapidly and fully assess the safety of newer agents in real-life patients.
Settore BIO/14 - Farmacologia
Settore MED/11 - Malattie Dell'Apparato Cardiovascolare
Settore MED/06 - Oncologia Medica
Bonura, F., Di Lisi, D., Novo, S., D'Alessandro, N. (2012). Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. CARDIOVASCULAR TOXICOLOGY, 12(2), 93-107 [10.1007/s12012-011-9141-z].
File in questo prodotto:
File Dimensione Formato  
Review Cardiovascular Toxicology.pdf

Solo gestori archvio

Descrizione: Articolo principale
Dimensione 265.73 kB
Formato Adobe PDF
265.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/63228
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact